DUOX2激活驱动IBD相关菌群失调中的细菌易位和亚临床炎症
该研究在小鼠模型和IBD患者样本中探讨上皮DUOX2活性对宿主和微生物组的功能影响,发现DUOX2活性升高增加肠道通透性和细菌易位并诱导亚临床炎症,丁酸盐和HDAC抑制剂可阻断DUOX2激活并逆转其效应。
要点
- DUOX2活性升高增加肠道通透性和细菌易位,并诱导亚临床炎症。
- IBD患者中DUOX2表达与血浆连蛋白水平正相关,与ZO-1表达负相关。
- 丁酸盐和HDAC抑制剂可阻断DUOX2激活并逆转其效应。
核心结论
- DUOX2信号升高促进上皮屏障功能障碍、微生物组改变和亚临床炎症,丁酸盐和HDAC抑制剂可逆转这些效应,提示DUOX2可能是IBD的治疗靶点。
研究设计与样本
- 研究使用上皮特异性DUOX2过度激活小鼠(vTLR4)、失活小鼠(vTLR4 DUOXA IEC-KO)和野生型对照,以及移植IBD或健康微生物群的无菌小鼠,结合结肠黏膜RNA测序、微生物群和粪便代谢组学分析,并在小鼠结肠类器官、IBD活检和患者血清样本中进行机制研究。
主要发现
- vTLR4小鼠中DUOX2活性增加通透性和细菌易位并诱导亚临床炎症。
- 无菌vTLR4小鼠DUOX2活性和通透性增加但无亚临床炎症。
- IBD患者中DUOX2表达与血浆连蛋白水平正相关,与ZO-1表达负相关。
- 移植IBD粪便的无菌小鼠DUOX2活性增加并触发低度炎症和通透性缺陷。
- DUOX2活性改变微生物组功能,减少丁酸盐代谢并促进促炎和促致癌细菌代谢物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel diseases (IBDs) are characterised by dysbiosis and a leaky gut. The NADPH oxidase dual oxidase 2 (DUOX2) is upregulated in patients with IBD, yet its role in driving the disease remains unclear. OBJECTIVE: We interrogated the functional consequences of epithelial DUOX2 activity for the host and microbiome. DESIGN: DUOX2 function was studied in mice with epithelial-specific DUOX2 overactivation (vTLR4), inactivation (vTLR4 DUOXA IEC-KO) and wild-type controls. We assessed the effect of dysbiosis on DUOX2 signalling and intestinal permeability (FITC-dextran, serum zonulin, bacterial translocation) with germ-free (GF) mice engrafted with IBD or healthy microbiota. RNA sequencing of colonic mucosa and microbiota and faecal metabolomics were used to characterise the host-microbe interface. Mechanistic studies were conducted in mouse colonoids, IBD biopsies and patient serum samples. RESULTS: DUOX2 activity increased permeability and bacterial translocation and induced subclinical inflammation in vTLR4 mice. GF vTLR4 mice had increased DUOX2 activity and permeability but no subclinical inflammation. In patients with IBD, DUOX2 expression was positively associated with plasma zonulin levels and negatively associated with ZO-1 expression. Engraftment of GF mice with IBD stool increased DUOX2 activity and triggered low-grade inflammation and permeability defects in mice. DUOX2 activity functionally altered the microbiome, reduced butyrate metabolism and promoted proinflammatory and pro-oncogenic bacterial metabolites. Butyrate and histone deacetylase (HDAC) inhibitors blocked DUOX2 activation and reversed its effects. CONCLUSIONS: Elevated DUOX2 signalling contributes to epithelial barrier dysfunction, microbiome alterations and subclinical inflammation. Butyrate and HDAC inhibitors reversed these effects, indicating that DUOX2 may be a therapeutic target in IBD.
引用
- Hazime H, Ducasa GM, Santander AM, et al. DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis. Gut. 2025. PMID: 40301115. doi:10.1136/gutjnl-2024-334346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。